Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
This study is not yet open for participant recruitment.
Verified May 2013 by National Institutes of Health Clinical Center (CC)
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
First received: July 19, 2012
Last updated: December 6, 2013
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is not yet open for participant recruitment.|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|